MDXH
MDxHealth·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 0
Consensus Rating "Strong Buy"
High Gross Profit Margin
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About MDXH
Mdxhealth Sa
A commercial-stage precision diagnostics company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer
CAP Business Center, Zone Industrielle des Hauts-Sarts, 4040 Herstal, Belgium
--
MDxHealth SA, a leader in molecular diagnostics, is a company that develops and commercializes advanced epigenetic analysis and service testing for cancer assessment and personalized treatment of patients. MDxHealth SA was established on January 10, 2003. The campaign is organized around two product families: (1) Epigenetic Molecular Testing (ConfirmMDx): a useful and innovative test that enables researchers to correctly identify and treat prostate cancer; and (2) Non-invasive liquid biopsy testing (SelectMDx): a test to assess the risk of aggressive prostate cancer during biopsy.
Earnings Call
Q3/2025
Estimate EPS-0.12
Actual EPS-0.16
Estimate Revenue27.83M
Actual Revenue27.40M
MDxHealth's Q3 2025 Earnings Call: Contradictions Emerge on Germline Focus, ExoDx Revenue, and Sales Strategy
Nov 12,2025 11:22
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
MDXH has released its 2025 Q3 earnings. EPS was reported at -0.16, versus the expected -0.12, missing expectations. The chart below visualizes how MDXH has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
MDXH has released its 2025 Q3 earnings report, with revenue of 27.43M, reflecting a YoY change of 17.65%, and net profit of -8.01M, showing a YoY change of 28.41%. The Sankey diagram below clearly presents MDXH's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
